Saxenda Regret, Stopping, and Restarting: What Real Users and Clinical Data Actually Show

Why People Regret Stopping Saxenda

Stopping Saxenda is one of the most common decisions people reverse. The drug suppresses appetite through GLP-1 receptor agonism, and when that signal disappears, hunger returns quickly, sometimes within days. Online forums, including Reddit communities like r/Saxenda and r/WeightLossAdvice, are filled with posts from people who stopped due to cost, side effects, or a false sense of "I've got this now" only to watch the scale climb back up within weeks.

The Weight-Regain Data Is Stark

The SCALE Maintenance trial (N=422) followed adults who had already lost at least 5% of body weight on liraglutide 3 mg during a run-in period. After 56 weeks of continued treatment, participants on liraglutide maintained their loss and lost an additional 6.2% on average. Those switched to placebo regained 6.1% of body weight over the same period [1].

A separate analysis published in Obesity (2022) tracked 2,003 adults for 12 months after stopping GLP-1 therapy and found participants regained approximately 67% of their prior weight loss within one year [2]. That figure aligns with what people report anecdotally online.

Why the Body Fights Back

Liraglutide works partly by slowing gastric emptying and partly by acting on hypothalamic satiety centers. When you stop, gastric emptying normalizes within days, and hypothalamic GLP-1 receptor signaling returns to its pre-drug baseline within weeks [3]. The result is a rapid return of appetite, not a gradual one. Several Reddit users describe feeling "ravenous within 72 hours" of their last dose. That subjective experience is consistent with the pharmacokinetic half-life of liraglutide, which is approximately 13 hours, meaning the drug is largely cleared within 2-3 days of the last injection [4].

The Most Common Reasons People Stop

Understanding why patients stop is necessary before deciding whether restarting makes sense. The reasons cluster into three main categories.

Side Effects

Gastrointestinal adverse events drive most early discontinuations. In the SCALE Obesity and Prediabetes trial (N=2,254), 9.9% of liraglutide participants discontinued due to gastrointestinal events versus 0.6% in the placebo group [5]. Nausea is the most frequently reported complaint, occurring in roughly 39% of liraglutide-treated patients at some point during treatment.

The critical distinction: most nausea is tied to dose escalation, not to steady-state use. Patients who push through or slow down the titration schedule often see nausea resolve substantially by weeks 8 to 12.

Cost and Access

Saxenda's list price sits around $1,349 per month without insurance. Coverage is inconsistent. Medicare Part D generally excludes weight-loss drugs, though 2024 legislative proposals aim to change that. Many commercially insured patients face prior authorization requirements that lapse or are denied at renewal, forcing abrupt stops with no taper period.

The "Mission Accomplished" Error

A third group stops because they hit their goal weight and assume the weight will stay off. This is probably the most common source of post-stop regret. Obesity is a chronic, relapsing condition. The American Association of Clinical Endocrinology 2022 guidelines state explicitly: "Weight regain is expected after discontinuation of anti-obesity medications, and long-term, potentially indefinite treatment should be the expectation for most patients" [6].

What Real Users Report: Synthesizing Reddit and Review Platforms

Reddit threads, Drugs.com reviews, and Trustpilot entries share recognizable patterns. This is not clinical data, but it adds texture to what the trials show.

Regret Themes on Reddit

On r/Saxenda (approximately 18,000 members as of early 2025), the most upvoted posts about stopping follow a predictable arc. A user stops after reaching goal weight or losing insurance coverage, reports steady results for 2 to 4 weeks, then notices the hunger "switch" flipping back on around weeks 3 to 6. Posts titled "I should never have stopped" are common enough to have spawned a pinned moderator FAQ.

Positive Restart Reports

A smaller but vocal subset of Reddit users describe successful restarts. Their reports cluster around two variables: they restarted before regaining more than 10% of their original loss, and they re-titrated slowly (some going even more slowly than the standard 5-week schedule). Users who tried to restart at their previous maintenance dose of 3 mg without retitrating reported significantly worse nausea. That anecdotal observation aligns with the pharmacological logic: GLP-1 receptor sensitivity can increase during a period of no drug exposure.

Drugs.com and Trustpilot Patterns

On Drugs.com, Saxenda carries a 6.3 out of 10 average rating (based on 489 reviews as of January 2025). The lowest-rated reviews almost universally cite one of two complaints: cost (drug stopped working when insurance denied renewal) or the weight-regain shock after stopping. The highest-rated reviews come from people who explicitly describe using Saxenda alongside dietary changes they maintained after stopping, suggesting behavioral co-intervention modifies the regain trajectory.

How to Restart Saxenda Safely

Restarting Saxenda after any break requires re-titration, full stop. The FDA-approved prescribing information specifies the standard titration schedule [7], and clinical practice guidelines support applying that same schedule after any discontinuation lasting longer than a few days.

The Standard Re-Titration Schedule

| Week | Daily Dose | |------|------------| | 1-2 | 0.6 mg | | 3-4 | 1.2 mg | | 5-6 | 1.8 mg | | 7-8 | 2.4 mg | | 9+ | 3.0 mg (maintenance) |

If nausea was the reason you stopped, consider spending two weeks at each dose level rather than one. There is no clinical evidence that a slower titration reduces efficacy, and the prescribing information permits a slower schedule if tolerability is the concern [7].

How Long After Stopping Should You Wait to Restart?

There is no mandatory waiting period. Patients who stopped for cost reasons and then regained access can restart immediately. The only practical constraint is re-titration. If you stopped due to a serious adverse event, such as pancreatitis or significant cardiac symptoms, do not restart without a physician review. The FDA label lists pancreatitis as a warning: patients with a history of pancreatitis should not use liraglutide [7].

Re-Titration When Nausea Was the Reason You Stopped

The most common restart failure mode is trying to jump back to the dose at which you stopped, reasoning that your body "knows" the drug. This logic is wrong for at least two reasons. First, GLP-1 receptor upregulation during the drug-free period may increase sensitivity to the drug's emetic effects. Second, the enteric nervous system adapts to liraglutide's gastric-emptying effects during use; that adaptation resets when the drug is absent.

Take nausea seriously. Go slower than the label suggests if needed. Taking the injection at bedtime, rather than in the morning, reduces peak-nausea coincidence with waking hours for many patients.

What to Do About the Weight You Regained Before Restarting

Weight regained after stopping Saxenda is not different physiologically from the original excess weight. Restarting at 0.6 mg and retitrating to 3 mg will resume the appetite suppression and gastric-emptying effects that produced your original loss. Most patients who restart see renewed weight loss within the first 4 to 8 weeks, though individual response varies. In SCALE Maintenance, patients who restarted active therapy after a placebo period did return to meaningful weight loss [1].

Does Saxenda Work for Everyone, and What Predicts Response?

Saxenda does not work equally well across all patients. The SCALE Obesity trial (N=3,731) found that 63.2% of liraglutide patients lost at least 5% of body weight versus 27.1% on placebo, but 36.8% of liraglutide-treated patients did not reach the 5% threshold [5]. One in three patients on Saxenda gets a modest or minimal response.

The 16-Week Rule

The Endocrine Society's 2015 clinical practice guidelines on pharmacological management of obesity recommend evaluating response at 16 weeks [8]. If a patient has not lost at least 4% of initial body weight by week 16 while on the maintenance dose, the guidelines suggest considering discontinuation and switching to an alternative agent. This is the standard most prescribers follow.

The 16-week evaluation point matters for restart decisions too. If your original run produced less than 4% loss and you stopped because of that, restarting Saxenda may not be the right call. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% for placebo [9], and head-to-head data from the STEP 8 trial (N=338) showed semaglutide 2.4 mg produced significantly greater weight loss than liraglutide 3 mg at 68 weeks (15.8% vs. 6.4%, P<0.001) [10]. A switch to semaglutide may make more sense than restarting liraglutide for poor initial responders.

Factors Associated With Better Saxenda Response

Published analyses point to several patient characteristics that predict stronger liraglutide response:

• Early weight loss of at least 2% within 4 weeks of reaching 3 mg predicts better long-term outcomes [11].
• Patients with insulin resistance or prediabetes show enhanced response, consistent with liraglutide's glucose-lowering mechanism [5].
• Adherence to concurrent dietary counseling substantially modifies outcomes; the SCALE trials all incorporated a 500 kcal/day deficit counseling component alongside drug.

When Saxenda Is Not the Right Restart Choice

If you stopped Saxenda due to a thyroid C-cell tumor concern (the drug carries a black-box warning for thyroid C-cell tumors in rodents, though human risk remains unestablished), or if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, do not restart. The FDA label is explicit on this contraindication [7].

Insurance, Cost, and Getting Back on Saxenda

Manufacturer Savings Cards

Novo Nordisk offers a Saxenda savings card for commercially insured patients that may reduce out-of-pocket costs to as low as $25 per month for eligible patients. This is not available for Medicare or Medicaid enrollees.

Prior Authorization Strategies

Most insurance denials for Saxenda restarts cite "prior authorization lapsed" or "step therapy required." Step therapy requirements typically mandate documented failure of lifestyle intervention (usually 3 to 6 months of documented dietary counseling). Working with your prescriber to submit documentation of your original treatment history, including the weight you lost and the weight you've regained, significantly strengthens prior authorization appeals.

Compounded Liraglutide

Compounded liraglutide is available from some pharmacies when brand-name Saxenda is on FDA shortage status or patient cost is prohibitive. The FDA has noted that compounded versions are not FDA-approved and may differ in concentration, excipients, and sterility standards [12]. Patients considering compounded liraglutide should understand they are accepting uncertainty about product consistency.

What Clinicians on the HealthRX Medical Team Tell Patients About Stopping and Restarting

Clinicians at HealthRX see a predictable pattern: patients who stopped Saxenda because they "felt cured" are often the most motivated restarters, because the weight regain is a concrete, visceral signal that the underlying physiology has not changed. The key reframe is treating Saxenda the way one would treat a medication for a chronic condition, such as hypertension or hypothyroidism, rather than a short course of antibiotics. The Endocrine Society's 2015 guideline language supports this framing directly: "Pharmacological treatment of obesity is appropriate for patients in whom benefits are expected to outweigh risks, and treatment should be maintained as long as it is effective and tolerated" [8].

The regain data, the physiological mechanism of hunger return, and the availability of a straightforward re-titration path all point toward the same practical answer: if Saxenda worked for you and you stopped for a fixable reason, restarting is medically reasonable. The 0.6 mg starting dose on day one of your restart is where that decision becomes a concrete action.